Net profit of Kwality Pharmaceuticals rose 10.92% to Rs 8.53 crore in the quarter ended December 2024 as against Rs 7.69 crore during the previous quarter ended December 2023. Sales rose 8.08% to Rs 84.41 crore in the quarter ended December 2024 as against Rs 78.10 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales84.4178.10 8 OPM %20.7321.36 - PBDT15.9514.57 9 PBT11.399.75 17 NP8.537.69 11 Powered by Capital Market - Live

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 31 January 2025.Powered by Capital Market - Live

Kwality Pharmaceuticals (KPL) has secured approval from the Review Committee on Genetic Manipulation (RCGM) to commence pre-clinical toxicity studies for its recombinant Erythropoietin product, 10,000 1U/mL, developed in its Biologics Unit. Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD). This milestone marks a significant step forward in our commitment to expanding our biologics portfolio and addressing critical healthcare needs. With this approval, Kwality Pharmaceuticals is on track to complete the pre-clinical studies and is diligently preparing for the commercialization of the product in the next fiscal. Powered by Capital Market - Live

Erythropoietin is a critical therapeutic used to treat anemia associated with chronic kidney disease (CKD). This milestone marks a significant step forward in our commitment to expanding our biologics portfolio and addressing critical healthcare needs. With this approval, Kwality Pharmaceuticals is on track to complete the preclinical studies and is diligently preparing for the commercialization of the product in the next fiscal. Kwality Pharmaceuticals is engaged in the business of manufacturers, buyers, and sellers of and dealers in all kinds of drug intermediates, chemicals, extracts, alkaloids, and other pharmaceutical goods, toilet requisites, medicines, beverages, and other medical preparations. The company's consolidated net profit surged 35.7% to Rs 8.47 crore on 29.3% jump in net sales to Rs 90.03 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

The approval was granted through a site transfer process for the company's prominent oncology oral solid dosage (OSD) product. This approval is a significant achievement in expanding the availability of this critical therapeutic, which plays a vital role in the treatment of hormone receptor-positive breast cancer. It reflects its ongoing commitment to providing high-quality, accessible oncology treatments to patients in key markets. The firm said, 'This approval further strengthens our presence in the High Regulated and global oncology market.' Kwality Pharmaceuticals is engaged in the business of manufacturers, buyers and sellers of and dealers in all kind of drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. The company's consolidated net profit surged 35.7% to Rs 8.47 crore on 29.3% jump in net sales to Rs 90.03 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

L-Asparaginase is an E. coli-derived enzyme primarily used in the treatment of acute lymphoblastic leukemia (ALL). The PEGylation process enhances the stability of the molecule and reduces the risk of allergic reactions, thereby improving patient outcomes and treatment efficacy. The company stated, 'This significant milestone underscores our commitment to delivering high-quality therapeutic solutions and marks an important step forward, as it is our first product from the biologics portfolio to be commercialized in both domestic and export markets', the firm stated. In addition, the company is actively engaged in discussions with leading domestic B2B companies to offer its PEGylated-Asparaginase on a CDMO (Contract Development and Manufacturing Organization) basis. These collaborations aim to leverage our manufacturing expertise, ensuring wider availability of this critical therapy. This approach not only strengthens local partnerships but also enhances patient access across various regions. Kwality Pharmaceuticals is engaged in the business of manufacturers, buyers and sellers of and dealers in all kind of drugs intermediates, chemicals, extracts, alkaloids and other pharmaceutical goods, toilet requisites, medicines, beverages and other medical preparations. The company's consolidated net profit surged 35.7% to Rs 8.47 crore on 29.3% jump in net sales to Rs 90.03 crore in Q2 FY25 over Q2 FY24. Powered by Capital Market - Live

Net profit of Kwality Pharmaceuticals rose 35.74% to Rs 8.47 crore in the quarter ended September 2024 as against Rs 6.24 crore during the previous quarter ended September 2023. Sales rose 29.26% to Rs 90.03 crore in the quarter ended September 2024 as against Rs 69.65 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales90.0369.65 29 OPM %21.8421.87 - PBDT17.1813.05 32 PBT12.558.17 54 NP8.476.24 36 Powered by Capital Market - Live

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 30 October 2024.Powered by Capital Market - Live

Kwality Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

Kwality Pharmaceuticals announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live